2 Information about benralizumab

Marketing authorisation indication

2.1 Benralizumab (Fasenra, AstraZeneca) is indicated as 'add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists'.

Dosage in the marketing authorisation

2.2 The recommended dosage is 30 mg every 4 weeks for the first 3 doses then every 8 weeks, given by subcutaneous injection using a pre-filled syringe.


2.3 The list price is £1,955 per 30‑mg pre-filled syringe (company submission). The company has a commercial arrangement. This makes benralizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)